StockData
Minerva Neurosciences, Inc. logo

Minerva Neurosciences, Inc. (NERV) stock

NERVNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30
$2.30−0.08 (-3.36%)

Close on Nov 13, 2026Market cap $109.82MP/E –Yield –

Minerva Neurosciences statistics

56 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.

Important dates

Next earnings
Mar 10, 2027 (estimated, before the open)
Last ex-dividend date
No dividends
Fundamentals through
Sep 30, 2026
Share price as of
Nov 13, 2026

Valuation ratiosIndustry

Market Cap
$109.82M
$272.32M
Enterprise Value
$32.87M
$146.23M

Share statisticsIndustry

Shares Change (YoY)
591.8%
10.8%
Shares Change (QoQ)
5.52%
0.50%
Float
46M
49M
Shares Held by Insiders
4.19%
11.7%
Shares Held by Institutions
88.6%
56.4%

Short sellingIndustry

Short Interest
2M
–
Short Interest Change
-21.2%
-0.80%
Short % of Float
4.15%
9.01%
Short % of Shares Outstanding
3.97%
6.30%
Days to Cover
10.46
5.15

Stock price statisticsIndustry

52-Week High
$8.80
–
52-Week Low
$1.96
–
20-Day Moving Average
$2.37
–
50-Day Moving Average
$3.01
–
200-Day Moving Average
$4.81
–
Average True Range (14)
$0.25
–
Price Change (1 Week)
-4.96%
-1.15%
Price Change (1 Month)
-4.96%
-4.87%
Price Change (3 Months)
-48.0%
-21.0%
Price Change (6 Months)
-55.9%
-20.6%
Price Change (YTD)
-42.8%
-23.6%
Price Change (1 Year)
-42.5%
-22.4%
Price Change (3 Years)
-52.8%
-29.5%
Price Change (5 Years)
-78.1%
-77.9%
Price Change (10 Years)
-97.9%
-65.4%
Average Volume (10 Days)
190,876
–
Average Volume (20 Days)
193,090
–
Average Volume (90 Days)
184,215
–
Relative Volume
0.40
0.70
Relative Strength Index (14)
40.3
43.4
Volatility (1 Year)
92.5%
80.1%
Beta (5 Years)
0.41
1.07

Returns on capitalIndustry

Return on Assets (ROA)
-460.3%
-40.6%
Return on Capital Employed (ROCE)
-43.6%
-37.9%

Financial positionIndustry

Current Ratio
33.02
3.30
Quick Ratio
30.46
2.39

EfficiencyIndustry

Profits Per Employee
-$41.55M
-$689.41K
Employee Count
7
74
WACC
7.60%
10.2%

Income statement (TTM)Industry

Operating Income
-$41.73M
-$21.37M
Net Income
-$290.86M
-$22.35M
EBITDA
-$41.73M
-$17.21M

Balance sheetIndustry

Net Cash (Debt)
$76.94M
$17.76M
Net Cash Per Share
$1.61
$0.80
Equity (Book Value)
-$97.52M
$53.89M
Book Value Per Share
-$2.04
$1.50
Tangible Book Value
-$112.39M
$27.13M
Working Capital
$80.88M
$79.99M

Cash flow (TTM)Industry

Operating Cash Flow
-$31.40M
-$12.38M

Dividends and yieldsIndustry

Earnings Yield
-264.9%
-21.8%

Scores and fair valueIndustry

Altman Z-Score
-9.97
0.23
Piotroski F-Score
3
4

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.

PeriodNERVS&P 500DifferenceNERV per yearS&P 500 per year
1 month-8.5%-3.0%−5.5 pts
3 months-41.3%-2.8%−38.5 pts
Year to date-42.8%+11.5%−54.3 pts
1 year-40.3%+13.5%−53.7 pts
3 years-41.9%+77.7%−119.6 pts-16.6%+21.1%
5 years-78.1%+72.6%−150.7 pts-26.2%+11.5%
10 years-97.9%+308.2%−406.0 pts-31.9%+15.1%

Short interest

Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.

2M NERV shares were sold short on Oct 30, 2026, down 21.2% from the previous report, or 4.15% of the shares available to trade. At recent volumes it would take 10.5 days to buy them back. Over the last 20 sessions, 54.9% of the volume reported to FINRA was short selling.

Settlement dateShares shortChangeAvg. daily volumeDays to cover
Oct 30, 20261,896,798-21.2%181,37810.5
Oct 15, 20262,407,249-1.2%129,74718.6
Sep 30, 20262,435,917+0.6%187,98413.0
Sep 15, 20262,421,652+14.6%120,27520.1
Aug 31, 20262,112,663+20.3%332,7556.3
Aug 14, 20261,755,972-28.3%149,36711.8
Jul 31, 20262,447,362+1.1%157,49515.5
Jul 15, 20262,420,231+27.1%193,28112.5
Jun 30, 20261,904,425+70.3%589,5723.2
Jun 15, 20261,118,602+13.8%105,48610.6
May 29, 2026982,569-17.2%173,0025.7
May 15, 20261,186,903-10.6%110,61610.7

Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.

See a number that looks wrong?